Welcome to our dedicated page for ROCHE HOLDING S/ADR news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on ROCHE HOLDING S/ADR stock.
Roche Holdings Ltd. S/ADR (RHHBY) is a leading biotechnology company with a global presence in the field of in-vitro diagnostics. Roche focuses on scientific excellence to develop medicines and diagnostics for improving and saving lives. The company's pivotal role in personalized healthcare is reflected in its commitment to transforming healthcare delivery. Roche's innovative approach encompasses the discovery and development of cutting-edge treatments, including the first CD20xCD3 bispecific antibody, Columvi® (glofitamab), for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company's recently FDA-cleared whole-slide imaging system, VENTANA DP 200, signifies Roche's dedication to revolutionizing pathology workflows through digitalization and artificial intelligence-based tools, ensuring pathologists can provide accurate and timely diagnoses. Roche's extensive portfolio and pipeline of haematology medicines demonstrate its unwavering commitment to advancing treatment options for patients worldwide.
Rhea-AI Summary
Roche's subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS. The Phase III study results show that the subcutaneous injection is consistent with IV infusion and achieves near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeks. The twice-yearly, 10-minute SC injection could expand OCREVUS usage to centers without IV infrastructure. Regulatory filings have been accepted by the FDA and EMA, with EU approval expected in mid-2024 and U.S. approval in September 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
-
Rhea-AI Summary
Genentech's Columvi meets primary endpoint of overall survival in people with relapsed or refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO study, showing significant improvement in survival rates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
-
Rhea-AI Summary
Roche's Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
Rhea-AI Summary
Roche's Elecsys pTau217 plasma biomarker test, developed in partnership with Eli Lilly and Company, receives Breakthrough Device Designation from the FDA. The test aims to identify amyloid pathology, aiding in early and accurate Alzheimer's diagnosis, potentially improving patient care and access to therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
-
Rhea-AI Summary
Roche receives CE Mark approval for VENTANA HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx to identify metastatic breast cancer patients with low HER2 expression, potentially benefiting from ENHERTU treatment. The test aids in assessing HER2-low status, expanding treatment options for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
-
Rhea-AI Summary
Roche's cobas Malaria test receives FDA approval for screening U.S. blood donors, offering a sensitive solution to detect Plasmodium parasites and improve blood safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
Rhea-AI Summary
Roche shareholders approve all Board proposals, re-elect Severin Schwan as Chairman, and increase dividend for the 37th consecutive year. The company reports strong performance in Pharmaceuticals and Diagnostics Divisions with a focus on oncology, immunology, neurology, and new areas like obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
-
Rhea-AI Summary
Roche introduces navify Analytics and Monitoring solutions for laboratories and point of care services, aiming to enhance operational efficiency and financial outcomes. The suite offers actionable insights to improve productivity, reduce costs, and optimize test turnaround times.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
-
Rhea-AI Summary
Roche and Alnylam's Phase II KARDIA-2 study of zilebesiran for hypertension met its primary endpoint, showing significant blood pressure reductions. The study demonstrated promising safety and tolerability, supporting potential twice-yearly dosing. The companies have initiated the Phase II KARDIA-3 study. Hypertension is a global health crisis with high mortality rates, affecting one in three adults worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
Rhea-AI Summary
Roche's Xolair shows promising results in treating food allergies in NIH-sponsored Phase III study, leading to FDA approval for expanded use in children and adults. The study reveals increased tolerance to peanuts, tree nuts, egg, milk, and wheat in multi-food allergic patients as young as 1 year old, reducing the risk of severe allergic reactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of ROCHE HOLDING S/ADR (RHHBY)?
The current stock price of ROCHE HOLDING S/ADR (RHHBY) is $35.44 as of November 22, 2024.
What is the market cap of ROCHE HOLDING S/ADR (RHHBY)?
The market cap of ROCHE HOLDING S/ADR (RHHBY) is approximately 230.4B.
What is Roche Holdings Ltd. S/ADR (RHHBY) known for?
Roche is a global leader in biotechnology, specializing in in-vitro diagnostics and the development of cutting-edge medicines.
What is the significance of Columvi® (glofitamab) in Roche's portfolio?
Columvi® (glofitamab) is the first CD20xCD3 bispecific antibody that has shown promising results in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
How does Roche contribute to personalized healthcare?
Roche aims to transform healthcare delivery by focusing on scientific excellence, data insights, and partnerships with stakeholders to provide tailored treatment options for patients.
What recent innovation has Roche introduced in digital pathology?
Roche's VENTANA DP 200 whole-slide imaging system, with FDA clearance, allows pathologists to review and interpret digital pathology images efficiently, facilitating remote diagnosis and collaboration.
What is Roche's approach to advancing haematology treatments?
Roche has a robust portfolio and pipeline of haematology medicines, including T-cell engaging bispecific antibodies like Columvi®, to address the diverse needs of patients with blood cancers.
ROCHE HOLDING LTD S/ADR